Drug Discovery

With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for

The aftermath of a spinal cord injury unleashes a devastating and prolonged biological assault, where the secondary damage cascade often proves more destructive than the initial physical trauma. This secondary injury process is a complex storm of excessive reactive oxygen species, relentless

A comprehensive global analysis has uncovered a troubling paradox in the fight against early-onset gastric cancer, a form of the disease striking individuals under the age of 50. While worldwide mortality rates have been steadily decreasing for decades, this positive trend masks a deepening and

A groundbreaking study from the University of Pittsburgh School of Medicine has illuminated a previously unknown immunological pathway that could fundamentally change how type 2 diabetes is treated, potentially offering a way to reverse the condition. As millions grapple with this chronic disease,

The battle against cancer is often depicted as a prolonged war of attrition, where treatments gradually weaken a tumor over time until it finally succumbs. But new research is uncovering a startling truth about ovarian cancer: the enemy’s most sophisticated defense shield may deploy the moment the

With the rise of GLP-1 agonists for weight management, the real-world patient experience often diverges from the neat narratives of clinical trials. To explore this complex landscape, we are speaking with biopharma expert Ivan Kairatov. Drawing on a recent analysis of hundreds of online user